Home ivps4 2017-06-16T21:39:52+00:00

Investors Home

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic.

Stock Info

Recent Press Releases

Recent News

Jun 11, 2019

Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial

3.0 mg, 3 times daily selected as dose for future clinical development SEATTLE and VANCOUVER, British Columbia, June 11, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a...

Jun 3, 2019

Achieve Receives $4.2 Million from Exercise of Warrants

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today...

May 30, 2019

Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline

Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today...